Arrowhead Pharmaceuticals (ARWR) Current Assets (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Current Assets came in at $1.8 billion in Q1 2026, up 62.06% YoY from $1.1 billion in Q1 2025, and up 56.66% on a QoQ basis from $1.2 billion in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Current Assets (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of Current Assets data on file, last reported at $1.8 billion in Q1 2026.
- Quarterly Current Assets rose 62.06% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 62.06% YoY) and the FY2025 annual result came in at $950.6 million, up 36.69% from the prior year.
- Current Assets advanced to $1.8 billion in Q1 2026, from $1.2 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $1.8 billion in Q1 2026 to a low of $237.9 million in Q4 2023.
- A 5-year average of $696.1 million and a median of $570.5 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets slumped 58.63% — and 2024, when it jumped 139.82%.
- Tracing ARWR's Current Assets over 5 years: stood at $575.0 million in 2022, then tumbled by 58.63% to $237.9 million in 2023, then soared by 139.82% to $570.5 million in 2024, then soared by 105.84% to $1.2 billion in 2025, then jumped by 56.66% to $1.8 billion in 2026.
- The last three Current Assets figures came in at $1.8 billion (Q1 2026), $1.2 billion (Q4 2025), and $950.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | 1.67 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.67 Bn |
| Mar 31, 2026 | 1.84 Bn |
| Dec 31, 2025 | 1.17 Bn |
| Sep 30, 2025 | 950.64 Mn |
| Jun 30, 2025 | 946.92 Mn |
| Mar 31, 2025 | 1.14 Bn |
| Dec 31, 2024 | 570.54 Mn |
| Sep 30, 2024 | 695.47 Mn |
| Jun 30, 2024 | 450.06 Mn |
| Mar 31, 2024 | 541.65 Mn |
| Dec 31, 2023 | 237.90 Mn |
| Sep 30, 2023 | 416.47 Mn |
| Jun 30, 2023 | 470.17 Mn |
| Mar 31, 2023 | 574.81 Mn |
| Dec 31, 2022 | 575.00 Mn |
| Sep 30, 2022 | 405.30 Mn |
| Jun 30, 2022 | 432.39 Mn |
| Mar 31, 2022 | 417.63 Mn |
| Dec 31, 2021 | 338.28 Mn |
| Sep 30, 2021 | 384.60 Mn |